A phocytes have been described in sera of human immunodeficiency virus (H1V)-infected patients.'"' It is not clear whether autoantibody formation is a result of polyclonal B-cell a~tivation"-'~ or whether it has pathogenetic relevance. T-cell autoantibodies were proposed as a cause of CD4 cell loss in HIV-infected patients: However, we found that autoantibody-negative patients also exhibited CD4 cell loss with disease progre~sion,'~ indicating that mechanisms other than autoantibodies must play a role in CD4 cell depletion. T-cell autoantibodies might influence T-cell functions by signal transmission to CD4 lymphocytes via binding to surface molecules. In CDC IV patients, Stricker et a19 found cytotoxic autoantibodies against mitogen-stimulated or HIV-infected CD4 cells that suppressed the proliferation of CD4-positive T cells in vitro. In contrast, in HIV-infected hemophilia patients we found no evidence of autoantibody-mediated suppression of T-cell proliferative responses after mitogenic or allogeneic ~timu1ation.l~ We reported previously that HIV-infected patients exhibited helper defects of CD4-positive T cells (25% of CDC 11, I11 patients, 83% of CDC IV patients), and that CD4 cells even suppressed control B-cell response^.'^ In the current study we investigated whether autoantibody formation against T cells or T subsets was accompanied by helper defects or suppressor activity of the respective subsets.
MATERIALS AND METHODS
Patient and control groups. Blood samples of 60 patients with hemophilia A or B and one patient with von Willebrand's disease were investigated. Forty patients (66%) were severely affected (factor VI11 or IX activity <1%), 17 (28%) were moderately (factor VI11 or IX activity 1% to 5%), and 4 (7%) were mildly affected (factor VI11 or IX activity >5%). The patients were treated with lyophilized commercial factor VI11 or IX concentrates; virus inactivated products were used since 1984. Twenty patients were HIV-negative and 41 patients HIV-positive (26 CDC stage 11,111; 15 CDC stage IV). Three CDC 11,111 patients and 10 CDC IV patients were treated with IgG 100 to 200 m a g intravenously every 2 weeks, and 11 CDC IV patients were treated or 111 patients; P < .02 in CDC IV patients). 12 of 13 patients with IgM autoantibodies and 4 of 4 with IgG autoantibodies showed CD4 helper defects. Complement fixation had no relevance. Autoantibody formation against CD4 cells was not due t o increased in vivo B-cell stimulation (spontaneous plaque formation: 611 2 204 PFC/lOE B cells in autoantibodynegative patients w650 rf: 202 PFC/106 B cells in autoantibodypositive patients; not significant). Thus, our results suggest that autoantibody formation is not caused by a general state of in vivo B-cell activation. Rather, the production of autoantibodies appears t o coincide with defects in B-cell proliferation or differentiation, as shown by reduced mitogen-stimulated B-cell responses in CDC II and 111 patients (P < .05). Autoantibodies against CD4 cells appear t o be involved in the pathogenesis of CD4 helper defects of HIV-infected patients.
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with oral zidowdine 4 x 200 mg/d. Twenty-five healthy blood donors served as controls.
IgG antibodies to HIV type 1 and 2 were determined at the Max-Pettenkofer-Institute (Munich, FRG) with enzyme-linked immunosorbent assay, Western blot, and immunofluorescence techniques. Antibodies to HIV type 2 were not detected in any patient.
Cell separations were performed as described previo~sly.'~,'~ Briefly, peripheral blood mononuclear cells were separated into "whole" T and non-T cells (termed B cells in the following) by rosetting with sheep red blood cells pretreated with 2-aminoethylisothiouronium bromide hydrobromide (Sigma, St Louis, MO). Whole T cells were separated further into CD4 cell-depleted and CD8 cell-depleted subsets (termed CD8+ and CD4+ subsets) by treatment with OKT4 or OKT8 monoclonal antibodies (MoAbs), respectively, and rabbit complement (Pel Freez, Rogers, AR). Our B-cell-enriched populations contained 2% to 5% CD2+ (OKT11') cells, 24% to 37% CD19+ (Leul2') cells, and 43% to 66% OKIa-l+ cells. T-cell-enriched subsets were 92% to 96% CD2+ and ~2 % CD19'. T cells treated with OKT8 MoAb and complement were 74% to 84% CD4' (OKT4') and 5 6 % CD8' (OKTV); T cells treated with OKT4 MoAb and complement were 70% to 77% CD8+ and I 10% CD4'. After a culture period of 6 days the cells were washed and plated in a reverse hemolytic plaque-forming cell (PFC) assay as described previously.'' T-and B-cell functions of patients were calculated from the results (PFC/1O6 B cells) of the following cocultures:
T cell or T-subset helper activity:
Plaque assay.
T cell or T-subset suppressor activity:
B(C) and T(C), B and T cells of a control; B(P), patient B cells; T(P), patient T cells, CD4
' or CD8' T-cell subsets, respectively; M, culture medium. Values under 10% helper function were defined as defective helper activity, values above 10% suppression as suppressor activity. The proportion of Ig-positive T cells ("whole" T, CD4', and CD8+ T cells) in peripheral blood was analyzed by double fluorescence and flow cytometry using a FACSCAN cytofluorograph (Becton Dickinson, Sunnyvale, CA). OKT3 (CD3, pan T lymphocytes), OKT4 (CD4, helpedinducer T cells), and OKT8 (CD8, suppressor/cytotoxic T cells; all antibodies from Ortho, Raritan, NJ) were used as first step antibodies. Ten microliters of antibody was added to 100 pL whole blood and incubated for 30 minutes at 4°C. After lysis of erythrocytes and two consecutive washing steps, 50 pL phycoerythrin-conjugated goatFlow cytometric analysis. 
Statistics.

RESULTS
T-cell autoantibodies.
Autoantibodies against CD4-positive T cells or whole T cells were not detected in controls or HIV-negative patients. However, we found T-cell autoantibodies in 9 of 26 (35%) CDC 11, I11 patients Table 3 . IgM, IgG, and C3d Binding Autoantibo and in 6 of 15 (40%) CDC IV patients, and autoantibodies against CD4 cells in 11 of 26 (42%) CDC 11, I11 patients and in 9 of 15 (60%) CDC IV patients (Table 1) . T-cell counts, CD4 cell counts, and CD8 cell counts were not significantly different in HIV-infected patients with or without autoantibodies against whole T cells, CDCpositive, or CD8-positive T cells (Table 1) . These results suggest that T-cell autoantibodies are not primarily involved in the depletion of T cells or certain T-cell subsets of HIV-infected patients. CD8 cell autoantibodies were found in 13 of 26 (50%) CDC 11, I11 patients and in 8 of 15 (53%) CDC IV patients, but also in 6 of 25 (24%) controls and in 3 of 20 (15%) HIV-negative patients ( Table 1) .
None of the controls or HIV-negative patients showed T or CD4 cell helper defects. In agreement with previous findings" we found T and CD4 helper defects in 11 of 26 (42%) and 10 of 21 (48%) CDC 11, I11 patients, respectively, and in 11 of 15 (73%) and 10 of 14 (71%) CDC IV patients, respectively. T and CD4 cells suppressed B-cell responses in 15 of 26 (58%) and 13 of 21 (62%) CDC 11, I11 patients, respectively, and in 12 of 14 (86%) CDC IV patients, but also in 2 of 25 (8%) controls and 4 of 20 (20%) HIV-negative patients. Thus, HIV-infected patients show helper defects and an enhanced suppressor activity of T cells, and this is true also for the CD4-positive T-cell subset.
T-cell autoantibodies and helper function. We found no significant association between the presence of autoantibodies against whole T cells and T-helper defects (Table 2) . However, 16 of 17 (94%) patients with autoantibodies against the CD4-positive subset exhibited a CD4 helper defect in contrast to only 4 of 18 (22%) patients without autoantibodies (P < .0001; Table 2 ). This finding was also significant in the subgroups of CDC 11, I11 and CDC IV patients (P < .002 and P < .02, respectively; Table 2 , Fig   1) . Examining Ig classes of CD4 cell autoantibodies, we found a helper defect in 12 of 13 patients with IgM and in 4 of 4 patients with IgG autoantibodies (Table 3) . Seven of seven patients with C'-fixing autoantibodies and 9 of 10 with non-C'-iixing autoantibodies showed CD4 helper defects (Table 3) CD4 cells is associated with a CD4 helper defect, irrespective of complement futation. Autoantibody formation against CD8 cells did not induce CD8 helper activity or abrogation of CD8 suppressor activity (Table 2) .
We found no significant association between the detection of autoantibodies against whole T cells or CD8-positive T cells and T or CD8 suppressor activity ( Fig 2) . However, this association was not found in the subgroup of CDC IV patients where nearly all patients showed CD4 suppressor activity regardless of autoantibody status (Table 4, Fig 2) . Furthermore, when IgM, IgG, C3d-binding, and non-C3d-binding autoantibodies against CD4 cells were analyzed separately, no significant relation was found with suppressor function (Table 5 ).
Time course of autoantibody formation and CD4 helper1 suppressor function. Autoantibody formation and CD4 helper/suppressor function was investigated in 13 HIVinfected patients at least twice over a period of 2 to 9 months. A new CD4 helper defect developed in 1 patient, and this was accompanied by newly detected IgM class CD4 autoantibodies (patient BH; Table 6 ). Helper defects were consistently detected in seven patients; five of them had persistent CD4 cell autoantibodies (patients OM, MN, SH, WW, HJ; Table 6 ) whereas two lost their autoantibodies in a second or third consecutive test (patients SE and WH; Table 6 ). In three patients helper defects were found in a first test but were no longer detected in subsequent tests (patients GS, FP, PJ; Table 6 ). Two of the three patients were consistently autoantibody-negative whereas the third lost his CD4 autoantibody when CD4 helper activity reappeared. Two patients were repeatedly autoantibodynegative and had normal helper function (patients HG and
T-cell autoantibodies and suppressor function.
LR; Table 6 ). Thus, CD4 helper defects appear to be associated with autoantibody formation against CD4 cells, but may persist despite autoantibody loss.
Suppressor activity of CD4 cells was independent of autoantibody formation in five patients: in one patient suppressor function was detected before autoantibodies occurred (patient BH; Table 6 For autoantibodies (patients GS, HG, LR; Table 6 ) or a loss of autoantibodies (patient SE; Table 6 ).
In vivo B-cell stimulation and autoantibody formation against CD4 cells. To investigate whether an enhanced state of in vivo B-cell activation might result in autoantibody formation against CD4 cells, we tested plaque responses of unstimulated B-cell cultures and unstimulated autologous B-and T-cell cocultures in 25 CDC 11, 111 patients and 15 CDC IV patients. We found no association between spontaneous B-cell responses of unstimulated cultures and autoantibody formation against CD4 cells (Fig  3) . However, in vitro B-cell responses of SAC I-and PWM-stimulated cultures were reduced in autoantibodypositive compared with autoantibody-negative CDC 11, I11 
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Helper Activity Suppressor Activity AbAb+ Abpatients (P = .05 and P < .OS, respectively; Fig 3) . Mitogenstimulated B-cell responses were reduced in CDC IV patients with or without autoantibodies (Fig 3) . infected patients without CD4 autoantibodies. Furthermore, time course studies showed that CD4 suppressor activity may occur independently of autoantibody formation. Thus, our data do not provide evidence that autoantibodies against CD4 cells induce CD4 suppressor activity. The enhanced CD4 suppressor activity in HIV-infected patients may be an effect of CD4 cell activation induced by HIV or other concurring viral infections."
A possible mechanism of autoantibody-induced CD4 helper defects is provided by Golding et aI,26,27 who described cross-reacting antibodies against highly conserved homologous regions of the HIV envelope protein gp41 and the fi chain of human HLA class I1 antigens. Data of Bost et ai2* suggest cross-reacting antibodies against homologous regions of gp41 and human interleukin-2 in the sera of HIV-infected patients. Both antibodies might affect the helper activity of CD4-positive T cells.
The CD4 autoantibodies detected by us using flow cytometry are not identical with the autoantibody described by Stricker et al,9 which, in contrast to our findings, was restricted to lectin-stimulated or HIV-infected CD4 cells and was not detected in asymptomatic HIV-infected patients. It has been suggested that autoantibody formation is just a result of the enhanced general state of B-cell activation found in HIV-infected patients. However, we found no association between plaque responses of unstimulated B-cell cultures and autoantibody formation against CD4 cells. Our data are consistent with the hypothesis that autoantibody formation is not caused by in vivo B-cell activation. Rather, it coincides with in vitro B-cell defects after mitogenic stimulation.
